Only in Titles

           Search results for: Insulin, human recombinant   

paperclip

#31952633   // Save this To Up

Effects of Epinephrine, Detomidine, and Butorphanol on Assessments of Insulin Sensitivity in Mares.

Sympathoadrenal stimulation may perturb results of endocrine tests performed on fractious horses. Sedation may be beneficial; however, perturbation of results may preclude useful information. Four experiments were designed to 1) determine the effects of epinephrine on insulin response to glucose (IR2G), 2) assess the effects of detomidine (DET), alone or combined with butorphanol (DET/BUT), on IR2G and glucose response to insulin (GR2I), and 3) assess the effects of BUT alone on IR2G. In Experiment 1, mares were administered saline or epinephrine (5 μg/kg BW) immediately before infusion of glucose (100 mg/kg BW). Glucose stimulated (P < .05) insulin release in controls at 5 minutes that persisted through 30 minutes; insulin was suppressed (P < .05) by epinephrine from 5 to 15 minutes, rising gradually through 30 minutes. Experiments 2 (IR2G) and 3 (GR2I) were conducted as triplicated 3 × 3 Latin squares with the following treatments: saline (SAL), DET, and DET/BUT (all administered at .01 mg/kg BW). Glucose stimulated (P < .05) insulin release that persisted through 30 minutes in SAL mares; DET and DET/BUT severely suppressed (P < .0001) the IR2G. Sedation did not affect resting glucose and had inconsistent effects on the GR2I when mares were treated with 50 mIU/kg BW recombinant human insulin. Butorphanol had no effect on IR2G. In conclusion, adrenergic agonists severely suppress the IR2G and cannot be used for sedation for this test. The use of DET did not alter the GR2I, and therefore may be useful for conducting this test in fractious horses.

2601 related Products with: Effects of Epinephrine, Detomidine, and Butorphanol on Assessments of Insulin Sensitivity in Mares.

Recombinant Human Insulin Rabbit Anti-Insulin Recep Bovine Insulin Powder GLP 1 ELISA Kit, Rat Gluc Rabbit Anti-Insulin Recep ElISA Human , Interleukin Insulin Antibody Rabbit Anti-Insulin Polyc ELISA Insulin ,Multispeci IGF-1R Signaling Phospho- Rabbit Anti-Insulin Polyc ELISA Insulin-U ,Mouse

Related Pathways

paperclip

#31951594   // Save this To Up

Paracrine senescence of human endometrial mesenchymal stem cells: a role for the insulin-like growth factor binding protein 3.

Stress-induced premature cell senescence is well recognized to be accompanied by emerging the senescence-associated secretory phenotype (SASP). Secreted SASP factors can promote the senescence of normal neighboring cells through autocrine/paracrine pathways and regulate the senescence response, as well. Regarding human endometrium-derived mesenchymal stem cells (MESCs), the SASP regulation mechanisms as well as paracrine activity of senescent cells have not been studied yet. Here, we examined the role of insulin-like growth factor binding protein 3 (IGFBP3) in the paracrine senescence induction in young MESCs. The HO-induced premature senescence of MESCs led to increased IGFBP3 in conditioned media (CM). The inhibitory analysis of both MAPK and PI3K signaling pathways showed that IGFBP3 releasing from senescent cells is mainly regulated by PI3K/Akt pathway activity. IGFBP3 appears to be an important senescence-mediating factor as its immunodepletion from the senescent CM weakened the pro-senescent effect of CM on young MESCs and promoted their growth. In contrast, young MESCs acquired the senescence phenotype in response to simultaneous addition of recombinant IGFBP3 (rIGFBP3). The mechanism of extracellular IGFBP3 internalization was also revealed. The present study is the first to demonstrate a significant role of extracellular IGFBP3 in paracrine senescence induction of young MESCs.

1236 related Products with: Paracrine senescence of human endometrial mesenchymal stem cells: a role for the insulin-like growth factor binding protein 3.

Rat monoclonal anti mouse Rat monoclonal anti mouse Epidermal Growth Factor ( Rat monoclonal anti mouse Epidermal Growth Factor ( Rat monoclonal anti mouse Rat monoclonal anti mouse Growth Differentiation Fa Hamster anti mouse Insuli zona pellucida binding pr Epidermal Growth Factor ( Mouse Anti-Human Retinol

Related Pathways

paperclip

#31932988   // Save this To Up

GH and IGF-1 Replacement in Children.

In this chapter, we want to give an overview on what we have learned from more than 30 years ago on the use of recombinant human growth hormone (rhGH) and later recombinant human IGF-1 which was introduced for the treatment of short children and what are the safety issues concerned with this treatment. However, rhGH is used not solely in conditions where short stature is the consequence of GH deficiency but also in various disorders without a proven GH deficiency. In clinical studies, growth responses to various forms of rhGH therapy were analyzed, adding to our concept about the physiology of growth. Most patients under rhGH treatment show a considerable short-term effect; however, the long-term gain of height in a child obtained by a year-long treatment until final height remains controversial in some of the growth disorders that have been treated with rhGH or IGF-1. Today the first studies on the long-term safety of rhGH treatment have been published and raising some questions whether this treatment is similarly safe for all the patient groups treated with rhGH. Although there is a long-standing safety record for these hormone replacement therapies, in the face of the considerable costs involved, the discussion about the risk to benefit ratio is continuing. Newer developments of rhGH treatment include long-term preparations, which have only to be injected once a week. Although some of these drugs already have proven their non-inferiority to conventional rhGH treatment, we have to await further results to see whether they show improvements in treatment adherence of the patients and prove their long-term safety.

2659 related Products with: GH and IGF-1 Replacement in Children.

SGI-1776 Mechanisms: PIM Rabbit Anti-Cell death in Recombinant Influenza (H5 Androgen Receptor , Mouse Rabbit Anti-Insulin Recep Mouse Anti-Insulin(1D4 ) Rabbit Plasma US Origin I PLX-4032 Mechanisms: B-Ra ELISA Monkey , Interleuki Rabbit Anti-intestinal FA Rabbit Anti-G protein alp Rabbit Anti-Phospho-INPPL

Related Pathways

paperclip

#31928223   // Save this To Up

Klotho supplementation ameliorates blood pressure and renal function in DBA/2-pcy mice, a model of polycystic kidney disease.

Klotho interacts with various membrane proteins such as receptors for transforming growth factor (TGF) β and insulin-like growth factor (IGF). Renal expression of klotho is diminished in polycystic kidney disease (PKD). In the present study, the effects of klotho supplementation on PKD were assessed.

1875 related Products with: Klotho supplementation ameliorates blood pressure and renal function in DBA/2-pcy mice, a model of polycystic kidney disease.

Renal disease spectrum ti Kidney disease spectrum ( Kidney cancer test tissue Kidney disease spectrum ( Kidney cancer survey tiss Skin disease tissue array Beta Amyloid (40) ELISA K Toxoplasma gondii GRA8, r Cervical carcinoma tissue Lung disease spectrum tis Rectum disease spectrum ( Kidney clear cell carcino

Related Pathways

paperclip

#31918694   // Save this To Up

Intein-mediated recombinant expression of monomeric B22Asp desB30 insulin.

Insulin controls hyperglycemia caused by diabetes, and virtually all treatments require exogenous insulin. However, the product's extensive post-translational modifications have hindered the manufacture of recombinant insulin.

2663 related Products with: Intein-mediated recombinant expression of monomeric B22Asp desB30 insulin.

pro-insulin recombinant p Recombinant Human Insulin Recombinant Human Insulin Recombinant Human Insulin insulin, human recombinan Recombinant Human Insulin Recombinant Mn SOD (Human Recombinant Human Insulin Insulin, human recombinan Recombinant Human Insulin Recombinant Human Myoglob Recombinant Human FABP3 P

Related Pathways

  •  
  • No related Items
paperclip

#31913613   // Save this To Up

F-Trifluoromethanesulfinate Enables Direct C-H F-Trifluoromethylation of Native Aromatic Residues in Peptides.

F labeling strategies for unmodified peptides with [F]fluoride require F-labeled prosthetics for bioconjugation more often with cysteine thiols or lysine amines. Here we explore selective radical chemistry to target aromatic residues applying C-H F-trifluoromethylation. We report a one-step route to [F]CFSONH from [F]fluoride and its application to direct [F]CF incorporation at tryptophan or tyrosine residues using unmodified peptides as complex as recombinant human insulin. The fully automated radiosynthesis of octreotide[Trp(2-CFF)] enables in vivo positron emission tomography imaging.

1555 related Products with: F-Trifluoromethanesulfinate Enables Direct C-H F-Trifluoromethylation of Native Aromatic Residues in Peptides.

Native Influenza HA (A Wi Native Influenza A Virus Native Influenza A Virus Prolactin-Inducible Prote Native Human C1 Esterase Native Influenza A Virus Native Influenza A Virus Native Influenza HA (A Pa Native Influenza A Virus Native Influenza A Virus Prostate cancer and hyper Recombinant Human Interle

Related Pathways

paperclip

#31908689   // Save this To Up

Gonadotropin versus Follicle-Stimulating Hormone for Ovarian Response in Patients Undergoing in vitro Fertilization: A Retrospective Cohort Comparison.

Poor ovarian responders generally refer to patients who respond poorly to ovarian stimulation for assisted reproductive techniques (ART) such as in-vitro fertilization (IVF) and hence experience low live birth rate. Various controlled ovarian stimulation (COS) protocols have been developed during the past 3 decades for IVF/ICSI to improve oocyte quality and ultimately live birth rate, to increase ovarian response in POR patients, and to reduce the risk of ovarian hyperstimulation syndrome. Both highly puri?ed human menopausal gonadotropin (hp-hMG) and recombinant follicle-stimulating hormone (rFSH) have been widely used for COS during IVF/ICSI. Their in?uence on treatment outcome in women undergoing IVF/ICSI hasbeen actively debated.

2230 related Products with: Gonadotropin versus Follicle-Stimulating Hormone for Ovarian Response in Patients Undergoing in vitro Fertilization: A Retrospective Cohort Comparison.

Anti beta3 AR Human, Poly Ovarian cancer test tissu Breast invasive ductal ca Resorufin Oleate, Fluorog GLP 1 ELISA Kit, Rat Gluc Rabbit Anti-Follicle Stim Human integrin aVb3, affi Ovarian disease spectrum Ovarian cancer tissue arr Ovarian cancer tissue arr Multiple lung carcinoma ( Mouse Anti-Follicle Stimu

Related Pathways

paperclip

#31904196   // Save this To Up

Reprogramming of human fibroblasts into osteoblasts by insulin-like growth factor-binding protein 7.

The induced pluripotent stem cell (iPSC) is a promising cell source for tissue regeneration. However, the therapeutic value of iPSC technology is limited due to the complexity of induction protocols and potential risks of teratoma formation. A trans-differentiation approach employing natural factors may allow better control over reprogramming and improved safety. We report here a novel approach to drive trans-differentiation of human fibroblasts into functional osteoblasts using insulin-like growth factor binding protein-7 (IGFBP7). We initially determined that media conditioned by human osteoblasts can induce reprogramming of human fibroblasts to functional osteoblasts. Proteomic analysis identified IGFBP7 as being significantly elevated in media conditioned with osteoblasts compared to those with fibroblasts. Recombinant IGFBP7 induced a phenotypic switch from fibroblasts to osteoblasts. The switch was associated with senescence and dependent on autocrine IL-6 signaling. Our study supports a novel strategy for regenerating bone by using IGFBP7 to trans-differentiate fibroblasts to osteoblasts.

1643 related Products with: Reprogramming of human fibroblasts into osteoblasts by insulin-like growth factor-binding protein 7.

Rat monoclonal anti mouse Rat monoclonal anti mouse Rat monoclonal anti mouse Rat monoclonal anti mouse Rat monoclonal anti mouse Human Insulin-like Growth Human Insulin-like Growth IGF1, Insulin-like growth Human Insulin-like Growth Human Growth and Differen Epidermal Growth Factor ( amyloid beta precursor pr

Related Pathways

paperclip

#31892750   // Save this To Up

Diabetic remission in a cat treated with an implantable pump to deliver insulin.

A diabetic cat was referred because of poor metabolic control and difficulties the owner experienced injecting insulin. A pump, telemetrically controlled with a smartphone, was implanted subcutaneously to deliver insulin. Before implantation, the pump reservoir was filled with a rapid-acting human recombinant insulin. The insulin was administered through continuous infusion or periodic boluses over 2 weeks while the cat was hospitalized and over another 2 weeks after discharge from the hospital. Adjustments of insulin dosage were performed based on blood glucose concentrations measured with a continuous blood monitoring system (CGMS). The cat achieved diabetic remission that is still lasting after 1 year. The treatment protocol adopted in this cat contributed to achieving remission. The owner's unwillingness to inject insulin into an uncooperative cat was circumvented with the implantable pump. Key clinical message: The implantable subcutaneous pump, telemetrically controlled by a smartphone, easily allowed the clinician to modify the type of administration and the amount of insulin delivered; the concurrent use of a CGMS allowed detection of sudden changes in blood glucose while limiting stress to the cat.

2004 related Products with: Diabetic remission in a cat treated with an implantable pump to deliver insulin.

Rabbit Anti-Insulin Recep Mouse Anti-Insulin(1G11) Rabbit Anti-Insulin Recep Mouse Anti-Insulin(1D4:) Rabbit Anti-Insulin Recep Mouse Anti-Insulin(1D4 ) Rabbit Anti-Insulin Recep Rabbit Anti-Insulin Recep Mouse anti human Insulin Rabbit Anti-Insulin Recep Rat monoclonal anti mouse Rabbit Anti-Insulin Polyc

Related Pathways

  •  
  • No related Items
paperclip

#31889346   // Save this To Up

Insulin-Delivery from Glucose-Responsive Self-Assembled Polyamine Nanoparticles: Smart "Sense-and-Treat" Nanocarriers Made Easy.

Polyamine-salt aggregates (PSA) are biomimetic soft-materials that have attracted great attention due to their straightforward fabrication methods, high drug-loading efficiencies and attractive properties for pH-triggered release. Here, a simple and fast multicomponent self-assembly process was used to construct crosslinked poly(allylamine hydrochloride)/phosphate PSAs  (hydrodynamic diameter of 360 nm) containing glucose oxidase enzyme, as a glucose-responsive element, and human recombinant insulin, as a therapeutic agent for the treatment of diabetes mellitus (GI-PSA). The addition of increasing glucose concentrations promotes the release of insulin due to the disassembly of the GI-PSAs triggered by the catalytic in-situ formation of gluconic acid. While under normoglycemia, the GI-PSA integrity remained intact for at least 24 h, hyperglycemic conditions produced a 100% of cargo releasing after 4 h of glucose addition. This entirely supramolecular strategy presents great potential for the construction of smart glucose-responsive delivery nanocarriers.

2599 related Products with: Insulin-Delivery from Glucose-Responsive Self-Assembled Polyamine Nanoparticles: Smart "Sense-and-Treat" Nanocarriers Made Easy.

GLP 1 ELISA Kit, Rat Gluc Insulin Glucose Phospho-S Aldehydo-D-glucose Phthal Rabbit Anti-Insulin Polyc Glucose 6 Phosphate Assay Bovine Insulin Rabbit Anti-Insulin Polyc T-antigen (Puro) lentivir Glucose Oxidase, Trinder, Mouse Anti-Insulin(1G11) D (+) Glucose anhydrous C Easy ELISA HRP Kit

Related Pathways